Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reversal of Bowel Obstruction With Platinum-Based Chemotherapy and Olaparib in Recurrent, Short Platinum-Free Interval, RAD51C Germline Mutation-Associated Ovarian Cancer.
Ngoi NYL, Tay D, Heong V, Thian YL, Ong PY, Ow SGW, Jeyasekharan AD, Lim YW, Lim SE, Lee SC, Ng J, Low JJH, Ilancheran A, Koh SZL, Tan DSP. Ngoi NYL, et al. Among authors: lim se, lim yw. JCO Precis Oncol. 2018 Nov;2:1-8. doi: 10.1200/PO.18.00008. JCO Precis Oncol. 2018. PMID: 35135172 No abstract available.
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.
Ngoi NYL, Heong V, Lee XW, Huang YQ, Thian YL, Choo BA, Lim D, Lim YW, Lim SE, Ilancheran A, Soong R, Tan DSP. Ngoi NYL, et al. Among authors: lim d, lim se, lim yw. Gynecol Oncol Rep. 2018 Jan 31;24:1-5. doi: 10.1016/j.gore.2018.01.009. eCollection 2018 May. Gynecol Oncol Rep. 2018. PMID: 29892689 Free PMC article.
Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01).
Ngoi NYL, Heong V, Tang JI, Choo BA, Kumarakulasinghe NB, Lim D, Low M, Lim SE, Lim YW, Leong YH, Tseng M, Tong PSY, Ilancheran A, Low JJH, Ng J, Thian YL, Koh V, Tan DSP. Ngoi NYL, et al. Among authors: lim d, lim se, lim yw. Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):701-711. doi: 10.1016/j.ijrobp.2020.09.059. Epub 2020 Oct 9. Int J Radiat Oncol Biol Phys. 2021. PMID: 33045316 Clinical Trial.
PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report.
Sachdeva M, Ngoi NYL, Lim D, Poon MLM, Thian YL, Lim YW, Lim SE, Tong P, Lum JHY, Ng J, Ilancheran A, Domingo EJ, Low JJH, Tan DSP. Sachdeva M, et al. Among authors: lim d, lim se, lim yw. Onco Targets Ther. 2021 Jun 29;14:3921-3928. doi: 10.2147/OTT.S309661. eCollection 2021. Onco Targets Ther. 2021. PMID: 34234460 Free PMC article.
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.
Yadav K, Lim J, Choo J, Ow SGW, Wong A, Lee M, Chan CW, Hartman M, Lim SE, Ngoi N, Tang SW, Ang Y, Chan G, Chong WQ, Tan HL, Tan SH, Goh BC, Lee SC. Yadav K, et al. Among authors: lim se, lim j. Breast Cancer Res Treat. 2022 Feb;192(1):131-142. doi: 10.1007/s10549-021-06470-7. Epub 2021 Dec 20. Breast Cancer Res Treat. 2022. PMID: 34928481 Free PMC article. Clinical Trial.
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.
Lee MX, Wong ALA, Ow S, Sundar R, Tan DSP, Soo RA, Chee CE, Lim JSJ, Yong WP, Lim SE, Goh BC, Wang L, Lee SC. Lee MX, et al. Among authors: lim se, lim jsj. Target Oncol. 2022 Mar;17(2):141-151. doi: 10.1007/s11523-022-00867-0. Epub 2022 Feb 23. Target Oncol. 2022. PMID: 35195837 Free PMC article. Clinical Trial.
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.
Lim JSJ, Wong ALA, Ow SGW, Ngoi NYL, Chan GHJ, Ang YLE, Chong WQ, Lim SE, Lim YW, Lee M, Choo JRE, Tan HL, Yong WP, Soo RA, Tan DSP, Chee CE, Sundar R, Yadav K, Jain S, Wang L, Tai BC, Goh BC, Lee SC. Lim JSJ, et al. Among authors: lim se, lim yw. Clin Cancer Res. 2022 Jun 1;28(11):2248-2256. doi: 10.1158/1078-0432.CCR-21-4179. Clin Cancer Res. 2022. PMID: 35363275 Clinical Trial.
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors.
Choo JRE, Jan YH, Ow SGW, Wong A, Lee MX, Ngoi N, Yadav K, Lim JSJ, Lim SE, Chan CW, Hartman M, Tang SW, Goh BC, Tan HL, Chong WQ, Yvonne ALE, Chan GHJ, Chen SJ, Tan KT, Lee SC. Choo JRE, et al. Among authors: lim se, lim jsj. Target Oncol. 2022 May;17(3):355-368. doi: 10.1007/s11523-022-00886-x. Epub 2022 Jun 14. Target Oncol. 2022. PMID: 35699834 Free PMC article.
Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia.
Low JL, Lim E, Bharwani L, Wong A, Wong K, Ow S, Lim SE, Lee M, Choo J, Lim J, Chan G, Walsh RJ, Muthu V, Ngoi N, Chong W, Tan SH, Lee SC. Low JL, et al. Among authors: lim e, lim se, lim j. Ther Adv Med Oncol. 2022 Dec 18;14:17588359221139678. doi: 10.1177/17588359221139678. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36570409 Free PMC article.
190 results